PLT Test Blog

I wrote several posts about why PAK1 inhibitors should be beneficial in some autism and indeed some schizophrenia. We also saw that PAK1-blocking drugs could be potentially useful for the treatment of neurofibromatosis type 2, in addition to RAS-induced cancers and neurofibromatosis type 1. One problem with drugs developed for cancer is that, even if they finally get approved, they tend to be ultra-expensive.  Production volumes are low because even if they “work” they do not prolong life for so long and cancer has numerous sub-types. Cheap drugs are ones used to treat common chronic conditions like high blood pressure, high cholesterol and indeed treatment of male lower urinary tract symptoms (LUTS), like benign prostatic hyperplasia (BPH). A small number of readers of this blog have confirmed the beneficial effect of PAK inhibitors in their specific sub-types of autism.  The problem is that there are no potent PAK1 inhibitors suitable for long term use that are readily avail...

  China, where things tend to be big, even their clinical trials A short while ago we looked at the possible mechanisms behind a reader’s successful experience in use of Mirtazapine (Remeron) in autism, then being prescribed to increase appetite. Mirtazapine is a tricyclic antidepressant, meaning it is very closely related to first generation antihistamines, but it has numerous other effects;  more of that later. Folate is vitamin B9.  Folic acid is synthetically produced, and used in   fortified foods   and   supplements   on the theory that it is converted into folate, which may not be the case. It appears that in both schizophrenia and autism there is a family of possible folate dysfunctions that range from minor to severe.  The mild dysfunction responds to a small supplement of folate, while the severe dysfunction requires a much larger supplement of folate. Roger, another reader of this blog has the more severe dysfunction called Cerebral Fol...